Home Page : www.otcjournal.com
Email Questions or Comments To:
editor@otcjournal.com
To
OTC Journal Members:
 |
Comments
in the BLOG |
 |
Today's edition focuses on the traditional
4th quarter rebound. In light of the market's sharp sell off in the last
two weeks, one can't help but wonder if the 4th quarter rally is in jeopardy
this year. I believe energy prices and the long end of the yield curve
will cause the inflection points one way or the other. More on this issue
below.
There are four new BLOG postings
for you to review. A few stocks are finally moving to tradable ranges.
I believe
DSEN, GEPT, and KAL are outstanding buys right
now. HDY and NWWV are breakouts- too late to buy. Here's
the headlines:
-
HDY: Coverage is reinitiated
in light of revelations concerning the offshore drilling program in Guinea.
I wouldn't pick it up now- it has traded up too high in the short term.
Comments in the BLOG. Click
here.
-
GEPT: The stock, which has been
very good to OTC Journal subscribers twice now, has finally dropped
to a tradable level. It is now a buy in my view. Click
Here for the BLOG entry.
-
DSEN: A sell of on very little
volume makes this one very attractive. The stock has rebounded off this
level twice for 40% gains. No reason why it shouldn't do it again. It is
a buy now in my view. Click
Here for the BLOG entry.
-
KAL: After trading up very nicely
in the first couple of post coverage weeks, this stock has recently swooned
a little with the market as a whole. News Saturday morning should have
a positive effect next week. More comments below.
-
NWWV: The stock traded big volume
and started moving up on Thursday and Friday. With the infomercial close
to rolling out, it's nice to see someone taking an interest. If you didn't
buy it when it was cheap and no one wanted it, it's too late unless it
pulls back and quiets down. Click
Here to read my comments.
To use the BLOG, simply go to
the home page at www.otcjournal.com
- the BLOG will scroll down automatically on the right side of your
screen. The most current journal entries appear in the middle of your screen.
Check back frequently for updates particularly when stocks are moving to
overbought or oversold levels or in volatile markets. Your questions and
postings do not automatically appear, so don't bother posting the same
question multiple times. I personally go through to moderate and respond
to every question.
Next week I will be out of touch.
Any questions for the BLOG postings need to go up this weekend.
I will bring it current on Monday and that will be it for the remainder
of the week. Also, no editions will be published. Be sure to keep your
eyes on your favorite stocks for news or events.
 |
FED Speak Hammers
Market: Update on Energy Price Rollover |
|
You have been asking for commentary
on the potentially impending rollover of energy prices, and here it is
today. Compliments of Adam Olensis at TheAgileTrader.com,
here are a couple of charts which gives us a picture of a pending short
term correction.
As you can see from the charts, both
oil and unleaded gas, as measured by November future prices, have rolled
over into corrective phases. This past week there was a relief rally predicated
on a forecast for increasing demand in '06- DUH!!- can you spell "already
priced into the market".
Thanks to an usual hurricane related
anomaly, oil and unleaded gas have traded somewhat independent of each
other. Nevertheless, both have started to roll over and are now making
a series of lower highs and lower lows.
I believe energy prices will either
correct with oil trading somewhere in the $52 to $58 range, or energy prices
will grind sideways for a period of about six months before resuming a
multi year climb. At this point it would take another natural disaster
to get energy prices headed higher.
While it's a big factor, energy prices
are not the only component driving non energy stocks down to 2005 lows.
I believe "FED Speak" is even a bigger culprit. There is nothing the market
hates more than the threat of inflation, and in the last two weeks several
FED governors have been publicly vocalizing concern over the issue.
This past week's CPI number was reasonably
tame, so statically speaking inflation, sans energy, is not too bad. Like
many, I believe the FED's mission here is to "talk up" the long end of
the yield curve. The FED has been raising short term interest rates, but
long term rates are controlled by the market. They have not been rising.
There is talk of an inverted yield curve, which is generally a leading
indicator that a recession is in the cards.
It seems to be working- FED Speak
is causing long term interest rates to rise a little, which should cool
off the red hot real estate market somewhat, and reduce the possibility
of core inflation.
Retracting energy prices combined
with slightly higher interest rates 10 years out should have the FED less
fearful of inflation and lead to a nice 4th quarter rally.
Increasing energy prices and stubbornly
low interest rates on the long end of the yield curve would create a poor
environment for non energy stocks, and the usual 4th quarter rally won't
come. It will be a tough market.
There will probably be one more "wash
and rinse" cycle. The market will tank, and CNBC will trot out every perrenial
bear. That will be the ideal point to buy.
|
Callisto
Pharmaceuticals (AMEX: KAL) Delivers Mission Statement |
|
On Saturday morning KAL issued
a press release which addresses investors questions about where this company
is headed for the remainder of '05 and into '06.
Amongst a number of new initiatives
is the pending new Phase II clinical trial for Annamycin, the company's
developing treatment for relapsed Leukemia, and the release of clinical
data concerning Antiprimod, KAL's developmental treatment for relapsed
multiple myeloma.
I continue
to believe KAL is significantly undervalued as compared to its peer
group, consisting of VION, BIVN, and CTIC. If the
stock achieves an average of these three comparables, a $4 to $5 stock
would result.
In any kind
of a reasonable market environment, the stock should trade better as clinical
data becomes available. Be in ahead of the crowd.
In the interim,
the stock has been in nice uptrend since early September, making a series
of higher highs and lower highs. Own this one for the speculative end of
your portfolio.
Here is the complete text of Saturday's
news for your review.
| Press Release Source:
Callisto Pharmaceuticals, Inc.
Callisto Outlines Key Goals and
Milestones in Strategic Initiatives Report for 2005-2006
Saturday October 15,
2:00 pm ET
Company Anticipates Commencement
of Next Stages of Preclinical and Clinical Research, Expansion of New Drug
Candidate Portfolio
NEW YORK--(BUSINESS WIRE)--Oct.
15, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL - News; FWB:CA4), a
developer of new drug treatments in the fight against hematological cancers
and related diseases, has detailed its overall business vision and major
goals in a Strategic Initiatives outlook for the coming 12 months. Chief
among the Company's strategic goals for the period is the expansion of
its portfolio of new drugs for global health care markets, and the acceleration
of clinical trials through 4Q 2005 and 2006 as it seeks to advance its
lead drug candidates in the clinic.
The Company's two anti-cancer
drug candidates Atiprimod and Annamycin are being developed to treat multiple
myeloma, and two forms of relapsed leukemia. The Company is also developing
a drug to treat inflammatory bowel disease, and has a homeland defense
initiative termed the Superantigen Biodefense Project that is exploring
development of a drug and vaccine to protect against biowarfare agents
from the class of Staphylococcus and Streptococcus pathogens.
"Callisto is focused
on vigorously advancing our clinical and pre-clinical programs throughout
2006," said Dr. Gary S. Jacob, CEO of Callisto. "We are committed to moving
forward with both Atiprimod and Annamycin to explore their potential in
treating multiple myeloma and leukemia, and at the same time, we are looking
to add to our drug pipeline of development programs to build a more durable
and robust future for the Company."
Callisto accomplished
a number of key milestones during the past 9 months, including:
*
Obtained orphan drug designation for Annamycin for both acute lymphoblastic
leukemia and acute myelogenous leukemia.
*
Announced in May, 2005, an interim analysis of the Atiprimod Phase I/IIa
clinical trial in relapsed or refractory multiple myeloma patients.
*
Established the Annamycin project team after successful in-licensing, and
accomplished all necessary goals to bring this drug forward into the clinic
to explore the drug's potential to treat relapsed leukemia.
*
Announced positive animal data on Callisto's GCRA drug SP340 in an animal
model of ulcerative colitis, and established the company's intention to
move SP304 forward for filing an investigational new drug application and
initiating a human trial in inflammatory bowel disease.
*
Received a $886,000 biodefense grant from NIAID to support further development
of Callisto's superantigen biodefense project.
The following are Callisto
Pharmceuticals' Strategic Initiatives for the coming 12 months:
Strategic Initiative
1 -- Pursue Human Clinical Trials for Annamycin
*
Callisto anticipates starting in 4Q 2005 an open-label single-agent clinical
trial of Annamycin in adult relapsed acute lymphoblastic leukemia patients.
Annamycin is an anti-cancer drug candidate from the anthracycline family,
which earlier completed a Phase I trial in refractory leukemia patients.
*
Commence a single agent trial of liposomal Annamycin in pediatric relapsed
ALL patients.
*
Commence a combination trial of liposomal Annamycin in combination with
Ara-C in adult relapsed acute myelogenous leukemia (AML) patients.
*
The Company will provide interim results on the first wave of Annamycin
clinical trials as these data come available in 2006.
Strategic Initiative
2 -- Further Clinical Development of Atiprimod
*
Callisto plans to announce up-to-date results on the Atriprimod Phase I/IIa
clinical trial in relapsed or refractory multiple myeloma patients. Clinical
and animal data will be presented at the American Society of Hematology
annual meeting in December, 2005, in Atlanta, Georgia.
*
Based on the results from the Phase I/IIa clinical trial, Callisto will
evaluate and plan further clinical development of Atiprimod.
Strategic Initiative
3 -- Expand Drug Portfolio
*
Callisto will continue to take steps to identify new proprietary drugs
and compounds in an effort to develop needed medical therapies for cancer
and other important health care markets.
*
The Company will seek promising in-licensing opportunities to extend its
IP portfolio with new drug candidates that present potential high-growth
revenue opportunities.
*
Callisto recently appointed Dan D'Agostino, a veteran investment banker
who has specialized in the biotechnology sector, to spearhead the Company's
M&A and corporate development activities to expand the Company's technology
and product portfolio. Mr. D'Agostino will also lead due-diligence efforts
as the Company identifies potential new drug candidates.
Strategic Initiative
4 -- Pursue Development of SP304 for Inflammatory Bowel Disease
# Based on encouraging
animal model data on Callisto's proprietary guanylate cyclase receptor
agonist SP304, the Company will continue to advance the preclinical development
of this innovative therapy with the intention of filing an investigational
drug (IND) application in late 2006.
Strategic Initiative
5 -- Continue Development of Superantigen Platform
*
Based on successful funding via an NIAID grant to support the Superantigen
program, the Company will continue its in-house development of the basic
technology along with additional animal model studies, in collaboration
with the U.S. Army Medical Research Institute of Infectious Diseases, necessary
to advance this program.
*
The Company will continue to explore strategic alternatives and partnerships
for expanding this effort to build the Superantigen-based biodefense program.
About Callisto Pharmaceuticals,
Inc.
Callisto is a biopharmaceutical
company focused on the development of drugs to treat cancer and osteolytic
bone disease. Callisto has two lead drugs in clinical development, Annamycin
to treat relapsed leukemia, and Atiprimod to treat relapsed multiple myeloma.
Callisto intends to initiate a clinical trial of Annamycin in relapsed
acute lymphoblastic leukemia patients in 4Q 2005. Annamycin, a drug from
the anthracycline family, has a novel therapeutic profile, including activity
against resistant diseases and significantly reduced cardiotoxicity. Callisto's
second drug, Atiprimod, is in a Phase I/IIa clinical trial in relapsed
multiple myeloma patients, and is a small-molecule, orally-available drug
with antiproliferative and antiangiogenic activity. Callisto also has drugs
in preclinical development for gastrointestinal inflammation, and a program
focused on the development of a drug to protect against staphylococcus
and streptococcus biowarfare agents. Callisto has exclusive worldwide licenses
from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture,
use and sell Atiprimod and Annamycin, respectively. For investor-specific
information about Callisto, including recent news and stock price data,
please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor
Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html.
To view an informational presentation of the Company's development pipeline
of drug candidates, visit http://www.trilogy-capital.com/tcp/callisto/powerpoint.html.
Callisto is also listed on the Frankfurt Stock Exchange under the ticker
symbol CA4. For additional information, visit www.callistopharma.com.
Forward-Looking Statements
Certain statements made
in this press release are forward-looking. Such statements are indicated
by words such as "expect," "should," "anticipate" and similar words indicating
uncertainty in facts and figures. Although Callisto believes that the expectations
reflected in such forward-looking statements are reasonable, it can give
no assurance that such expectations reflected in such forward-looking statements
will prove to be correct. As discussed in the Callisto Pharmaceuticals
Annual Report on Form 10-K/A for the year ended December 31, 2004, and
other periodic reports, as filed with the Securities and Exchange Commission,
actual results could differ materially from those projected in the forward-looking
statements as a result of the following factors, among others: uncertainties
associated with product development, the risk that products that appeared
promising in early clinical trials do not demonstrate efficacy in larger-scale
clinical trials, the risk that Callisto will not obtain approval to market
its products, the risks associated with dependence upon key personnel and
the need for additional financing.
Contact:
Callisto Pharmaceuticals, Inc.
Dan D'Agostino, 212-297-0010 ext. 227
dagostino@callistopharma.com
or
Trilogy Capital Partners, Inc.
Paul Karon, 800-592-6067 (Investor Relations)
paul@trilogy-capital.com
Source: Callisto Pharmaceuticals,
Inc. |
|
Subscribe |
|
Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription.
Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.
To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best
way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable
email newsletter delivery.
Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.
|
